On ECHEMI
Home > Drugs > Fleroxacin Injection

Fleroxacin Injection

Function and Efficacy

This product is a fluoroquinolone antibacterial drug. It has strong antibacterial effects on Gram-negative bacteria, including Escherichia coli, Klebsiella pneumoniae, Proteus, Salmonella typhi, Salmonella paratyphi, Shigella, Enterobacter cloacae, Enterobacter aerogenes, Citrobacter, Serratia marcescens, Pseudomonas aeruginosa, Neisseria meningitidis, Haemophilus influenzae, Moracata, Legionella pneumophila, Neisseria gonorrhoeae, etc. It also has moderate antibacterial effects on Gram-positive cocci such as Staphylococcus and hemolytic Streptococcus. In recent years, bacterial resistance to fluoroquinolones has increased significantly, especially in Escherichia coli, with a resistance rate of more than 50%. The mechanism of action of this product is to inhibit the bacterial DNA gyrase and thus kill bacteria.

Ingredients

Fleroxacin: 6,8-difluoro-1-(2-fluoroethyl)-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid. [Molecular formula] C17H18F3N3O3 [Molecular weight] 369.34

Name Description Content CAS NO. Manufacturer
FleroxacinIngredients

This product is a fluoroquinolone antibiotic that has antibacterial effects on Gram-negative bacteria and some Gram-positive cocci, and has a bactericidal effect by inhibiting bacterial DNA gyrase.

More
79660-72-3 6

Indication

It can be used for the following respiratory infections caused by bacteria that are sensitive to this product: acute bronchitis, acute exacerbation of chronic bronchitis, pneumonia, etc.; urogenital system infections such as cystitis, pyelonephritis, prostatitis, epididymitis, gonorrhea Neisseria urethritis, etc.; digestive system infections such as typhoid Salmonella infection, bacterial dysentery, etc.; skin and soft tissue infections, bone infections, abdominal infections and pelvic infections, etc.

Usage and Dosage

Inject slowly by intravenous drip in a dark place, 0.2-0.4 g at a time, once a day, diluted in 250-500 ml of 5% glucose injection.

Adverse Reactions

1. Gastrointestinal reactions are relatively common and may manifest as abdominal discomfort or pain, diarrhea, nausea, vomiting, and loss of appetite. 2. Central nervous system reactions may include dizziness, headache, excitement, drowsiness, or insomnia. 3. Allergic reactions include rash, skin itching, and occasionally exudative erythema multiforme and angioneurotic edema. A small number of patients have photosensitivity reactions. 4. A small number of patients may experience increased blood aminotransferase and blood urea nitrogen and decreased peripheral white blood cells, which are mostly mild and transient. 5. Occasionally, the following may occur: 1. Epileptic seizures, mental abnormalities, irritability, confusion, hallucinations, and tremors. 2. Manifestations of interstitial nephritis such as hematuria, fever, and rash. 3. Crystalluria, more common when used in high doses. 4. Joint pain. 5. Phlebitis.

Precautions

1. Those who are allergic to this product or quinolones are contraindicated. 2. Pregnant women, lactating women and patients under 18 years old are contraindicated. [Use in pregnant and lactating women] Fluoroquinolones can pass through the blood-placental barrier and can be secreted into breast milk. Their concentration is close to the blood drug concentration, so pregnant and lactating women are contraindicated. [Use in children] Fluoroquinolones can cause permanent damage to the weight-bearing joint cartilage of dogs and cause lameness. They can also cause arthritis in several other minor animals, so they are contraindicated for patients under 18 years old. In infections caused by multidrug-resistant bacteria, when the bacteria are only sensitive to fluoroquinolones, this product can be used in children after weighing the pros and cons. [Use in the elderly] Elderly patients have reduced renal function, and the dosage should be reduced as appropriate.

Drug Interactions

1. The aluminum and magnesium contained in didanosine (DDI) preparations can chelate with fluoroquinolones and should not be used together. 2. Urine alkalinizers can reduce the solubility of this product in urine, leading to crystalluria and nephrotoxicity. 3. Probenecid can delay the excretion of this product, increase the blood concentration of this product and produce toxicity.

Storage

Keep away from light and store in a sealed container.

Packaging Specification

10ml:0.2g

Manufacturer

Shijiazhuang Yiling Pharmaceutical Co., Ltd.

  • Founded in:

    2001-08-28
  • Address:

    No. 238 Tianshan Street, Shijiazhuang High-tech Development Zone
  • Tax NO.:

    9113000023565800XC
  • Registered Funds:

    1670.705376 yuan
  • Website:

  • Email:

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.